A portrait illuminates a metaphor for maldistribution of burden of disease, risk exposure, and long-standing inequity in health laid bare to the world during the COVID-19 pandemic.
AMA J Ethics. 2021;23(3):E283-284. doi:
10.1001/amajethics.2021.283.
For health professions and ethics journals, decisions about what is published and promoted profoundly influence humanity’s well-being across time and place.
AMA J Ethics. 2021;23(6):E501-504. doi:
10.1001/amajethics.2021.501.
American visual and narrative representations of Native experiences suggest an obligation to look on 19th-century White American artists’ romanticizations of those experiences with humility.
AMA J Ethics. 2020;22(10):E898-903. doi:
10.1001/amajethics.2020.898.
Pharma has long marketed opioids in ways that contribute to opioid use disorder and deaths by overdose. Regulatory mistakes in approving and labeling new analgesics by the FDA didn’t make us safer.
AMA J Ethics. 2020;22(8):E743-750. doi:
10.1001/amajethics.2020.743.
Annette Hanson, MD, Ron Pies, MD, and Mark Komrad, MD
Authors respond to “How Should Physicians Care for Dying Patients with Amyotrophic Lateral Sclerosis?” by arguing that patients’ motives for accessing death with dignity laws should be thoroughly explored and that temporarily limiting patient autonomy can promote well-being at the end of life.
AMA J Ethics. 2018;20(11):E1107-1109. doi:
10.1001/amajethics.2018.1107.
Alexander Craig, MPhil and Elizabeth Dzeng, MD, PhD, MPH
Responding to “Added Points of Concern about Caring for Dying Patients,” authors argue that physicians’ refusal to prescribe lethal drugs in accordance with states’ death with dignity laws could damage patient-physician relationships and harm patients.
AMA J Ethics. 2018;20(11):E1110-1112. doi:
10.1001/amajethics.2018.1110.